News

Mltidisciplinary Masterclass dedicated to prostate and bladder cancers

8 July 2022 -

Multidisciplinary Masterclass organized by the American Hospital in Paris, MEDIPATH and Ibex Medical Analytics dedicated to prostate and bladder…

VitaDX and MEDIPATH collaborate to deploy VisioCyt® , an innovative solution for the early diagnosis of bladder cancer

6 July 2022 -

Publishing

VitaDX is proud to announce its partnership with Medipath, a group of independant pathologists specialized in locally based diagnostics and…

VitaDX is delighted to have been a part of the Bits & Pretzels HealthTech Conference!

29 June 2022 -

News

During the conference Bits & Pretzels HealthTech, Allan Rodriguez - CEO of VitaDX had the opportunity to participate in a panel discussion…

VitaDX was delighted to attend the TechShare Campus in Lisbon

23 June 2022 -

News

VitaDX was delighted to attend the TechShare Campus in Lisbon as part of Euronext pre-IPO program and to be one of the 132 Tech companies from 10…

International and French Oncology Days

22 June 2022 -

News

VitaDX was very delighted to participate in the "Biotech in Oncology" exchange on the theme of accelerating oncology projects.

JOUM 2022

17 June 2022 -

News

VitaDX participated to the JOUM (Medical Onco-Urology Days) which took place from June 17 to 18, 2022 in Toulouse.

Tour of France SASN

15 June 2022 -

News

As part of its Tour de France of the "Digital Health" acceleration strategy around the theme: health data, Allan Rodriguez - CEO of VitaDX…

VitaDX is proud to announce that the abstract of its first clinical trial VISIOCYT 1 has been selected at ASCO 2022

11 June 2022 -

News

VitaDX is proud to announce that the abstract of its first clinical trial VISIOCYT 1 has been selected at ASCO 2022.

May «Bladder Cancer Awareness Month»

31 May 2022 -

News

On this last day of May «Bladder Cancer Awareness Month», the entire VitaDX team reiterates its support to patients by working every day to…

Mltidisciplinary Masterclass dedicated to prostate and bladder cancers

8 July 2022 -

News

Multidisciplinary Masterclass organized by the American Hospital in Paris, MEDIPATH and Ibex Medical Analytics dedicated to prostate and bladder…

VitaDX and MEDIPATH collaborate to deploy VisioCyt® , an innovative solution for the early diagnosis of bladder cancer

6 July 2022 -

Publishing

VitaDX is proud to announce its partnership with Medipath, a group of independant pathologists specialized in locally based diagnostics and…

VitaDX is delighted to have been a part of the Bits & Pretzels HealthTech Conference!

29 June 2022 -

News

During the conference Bits & Pretzels HealthTech, Allan Rodriguez - CEO of VitaDX had the opportunity to participate in a panel discussion…

VitaDX was delighted to attend the TechShare Campus in Lisbon

23 June 2022 -

News

VitaDX was delighted to attend the TechShare Campus in Lisbon as part of Euronext pre-IPO program and to be one of the 132 Tech companies from 10…

International and French Oncology Days

22 June 2022 -

News

VitaDX was very delighted to participate in the "Biotech in Oncology" exchange on the theme of accelerating oncology projects.

JOUM 2022

17 June 2022 -

News

VitaDX participated to the JOUM (Medical Onco-Urology Days) which took place from June 17 to 18, 2022 in Toulouse.

Tour of France SASN

15 June 2022 -

News

As part of its Tour de France of the "Digital Health" acceleration strategy around the theme: health data, Allan Rodriguez - CEO of VitaDX…

VitaDX is proud to announce that the abstract of its first clinical trial VISIOCYT 1 has been selected at ASCO 2022

11 June 2022 -

News

VitaDX is proud to announce that the abstract of its first clinical trial VISIOCYT 1 has been selected at ASCO 2022.

May «Bladder Cancer Awareness Month»

31 May 2022 -

News

On this last day of May «Bladder Cancer Awareness Month», the entire VitaDX team reiterates its support to patients by working every day to…